Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric current may boost Methotrexate's power against vitiligo

NCT ID NCT07208890

Disease control Sponsor: Pharos University in Alexandria Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two ways of delivering methotrexate to treat vitiligo patches: using a low-intensity electric current (iontophoresis) versus a standard gel. Thirty adults with stable vitiligo will be randomly assigned to one of the two treatments for 8 weeks. Researchers will measure how much skin color returns and track quality of life and liver safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methotrexate
What this could lead to
If it works, this could offer a more effective, localized treatment for vitiligo with fewer side effects than oral methotrexate.
What could go wrong
This is a small, early pilot study with only 30 people, so results may not apply widely. The treatment may not cause significant repigmentation, and liver function must be monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Clinically diagnosed vitiligo confirmed by a dermatologist. Stable vitiligo for at least 6 months (no new lesions or progression). Age between 18 and 60 years. Both male and female patients. Presence of localized or segmental vitiligo suitable for topical treatment. Willingness to avoid other vitiligo treatments (e.g., phototherapy, corticosteroids) during the study period. Able and willing to provide written informed consent and comply with study procedures - Exclusion Criteria:History of systemic or topical methotrexate use within the past 3 months. Unstable or rapidly progressive vitiligo during the last 6 months. Presence of other autoimmune or dermatologic disorders that could interfere with study evaluation (e.g., psoriasis, eczema, lupus). Known hypersensitivity or allergy to methotrexate or any gel/iontophoresis components. Hepatic, renal, or hematologic impairment (abnormal liver function or renal profile). Pregnant or breastfeeding women, or those planning pregnancy during the study period. Use of phototherapy, corticosteroids, or immunosuppressive therapy within the last 3 months. Metal implants or pacemakers, which may contraindicate iontophoresis \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo - evaluation of methotrexate iontophoresis and topical methotrexate gel as localized treatment approache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo - evaluation of methotrexate iontophoresis and topical methotrexate gel as localized treatment approache

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.